{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:37:26Z","timestamp":1778711846001,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier","isbn-type":[{"value":"9780323900188","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.mcb.2022.04.002","type":"book-chapter","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T23:00:12Z","timestamp":1656543612000},"page":"1-22","source":"Crossref","is-referenced-by-count":0,"title":["Multiple gene knockdown strategies for investigating the properties of human leukemia stem cells and exploring new therapies"],"prefix":"10.1016","member":"78","reference":[{"issue":"6","key":"10.1016\/bs.mcb.2022.04.002_bb0010","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1158\/1078-0432.CCR-14-2146","article-title":"Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations","volume":"21","author":"Alvarez-Calderon","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"35","key":"10.1016\/bs.mcb.2022.04.002_bb0015","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1039\/C7TB01833A","article-title":"Biomaterials for polynucleotide delivery to anchorage-independent cells","volume":"5","author":"Ansari","year":"2017","journal-title":"Journal of Materials Chemistry B"},{"issue":"6","key":"10.1016\/bs.mcb.2022.04.002_bb0020","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.mcb.2022.04.002_bb0025","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"355","key":"10.1016\/bs.mcb.2022.04.002_bb0030","doi-asserted-by":"crossref","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Science Translational Medicine"},{"issue":"6","key":"10.1016\/bs.mcb.2022.04.002_bb0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex","volume":"105","author":"Chen","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"10.1016\/bs.mcb.2022.04.002_bb0040","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.mcb.2022.04.002_bb0045","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"The Journal of Clinical Investigation"},{"issue":"5","key":"10.1016\/bs.mcb.2022.04.002_bb0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/bs.mcb.2022.04.002_bb0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1042\/BJ20130950","article-title":"Advances in siRNA delivery to T-cells: Potential clinical applications for inflammatory disease, cancer and infection","volume":"455","author":"Freeley","year":"2013","journal-title":"Biochemical Journal"},{"issue":"5","key":"10.1016\/bs.mcb.2022.04.002_bb0060","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.12532","article-title":"Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up","volume":"163","author":"Gallipoli","year":"2013","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1016\/bs.mcb.2022.04.002_bb0065","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/bjc.2012.142","article-title":"Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: Simulation studies of different treatment combinations","volume":"106","author":"Glauche","year":"2012","journal-title":"British Journal of Cancer"},{"issue":"15","key":"10.1016\/bs.mcb.2022.04.002_bb0070","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014Advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"The New England Journal of Medicine"},{"issue":"5531","key":"10.1016\/bs.mcb.2022.04.002_bb0075","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1016\/bs.mcb.2022.04.002_bb0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.mcb.2022.04.002_bb0085","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.leukres.2014.08.008","article-title":"Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells","volume":"38","author":"Gul-Uludag","year":"2014","journal-title":"Leukemia Research"},{"issue":"6","key":"10.1016\/bs.mcb.2022.04.002_bb0090","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.mcb.2022.04.002_bb0095","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/bs.mcb.2022.04.002_bb0100","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","article-title":"Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli","volume":"19","author":"Holtz","year":"2005","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/bs.mcb.2022.04.002_bb0105","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: Stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"issue":"24","key":"10.1016\/bs.mcb.2022.04.002_bb0110","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/bs.mcb.2022.04.002_bb0115","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells","volume":"99","author":"Jiang","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"10.1016\/bs.mcb.2022.04.002_bb0120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/bs.mcb.2022.04.002_bb0125","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.mcb.2022.04.002_bb0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2015.12.052","article-title":"Targeting CXCR4\/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia","volume":"224","author":"Landry","year":"2016","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/bs.mcb.2022.04.002_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.13","article-title":"Progress in RNAi-mediated molecular therapy of acute and chronic myeloid leukemia","volume":"4","author":"Landry","year":"2015","journal-title":"Molecular Therapy--Nucleic Acids"},{"issue":"5","key":"10.1016\/bs.mcb.2022.04.002_bb0140","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/blood.2019003636","article-title":"The miR-185\/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.002_bb0145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-1-62703-128-8_15","article-title":"Human long-term culture initiating cell assay","volume":"946","author":"Liu","year":"2013","journal-title":"Methods in Molecular Biology"},{"issue":"1","key":"10.1016\/bs.mcb.2022.04.002_bb0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/bloodadvances.2017015511","article-title":"Fluorescent labeling of CRISPR\/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response","volume":"3","author":"Nasri","year":"2019","journal-title":"Blood Advances"},{"issue":"26","key":"10.1016\/bs.mcb.2022.04.002_bb0155","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood.2020007651","article-title":"Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia","volume":"137","author":"Niu","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.mcb.2022.04.002_bb0160","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"issue":"7569","key":"10.1016\/bs.mcb.2022.04.002_bb0165","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/bs.mcb.2022.04.002_bb0170","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.mcb.2022.04.002_bb0175","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2010.02.020","article-title":"Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems","volume":"144","author":"Rothdiener","year":"2010","journal-title":"Journal of Controlled Release"},{"issue":"1","key":"10.1016\/bs.mcb.2022.04.002_bb0180","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.stem.2020.04.005","article-title":"Integrin-linked kinase mediates therapeutic resistance of quiescent CML stem cells to tyrosine kinase inhibitors","volume":"27","author":"Rothe","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"23","key":"10.1016\/bs.mcb.2022.04.002_bb0185","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1182\/blood-2013-07-516807","article-title":"The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem\/progenitor cells","volume":"123","author":"Rothe","year":"2014","journal-title":"Blood"},{"issue":"5405","key":"10.1016\/bs.mcb.2022.04.002_bb0190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.mcb.2022.04.002_bb0195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","article-title":"Getting to the stem of chronic myeloid leukaemia","volume":"8","author":"Savona","year":"2008","journal-title":"Nature Reviews. Cancer"},{"issue":"11","key":"10.1016\/bs.mcb.2022.04.002_bb0200","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2010.159","article-title":"Insights into the stem cells of chronic myeloid leukemia","volume":"24","author":"Sloma","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/bs.mcb.2022.04.002_bb0205","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","article-title":"Biology and relevance of human acute myeloid leukemia stem cells","volume":"129","author":"Thomas","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.002_bb0210","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2019.08.018","article-title":"siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers","volume":"310","author":"Valencia-Serna","year":"2019","journal-title":"Journal of Controlled Release"},{"issue":"1","key":"10.1016\/bs.mcb.2022.04.002_bb0215","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41467-021-21650-1","article-title":"Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics","volume":"12","author":"Velten","year":"2021","journal-title":"Nature Communications"},{"issue":"10","key":"10.1016\/bs.mcb.2022.04.002_bb0220","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/leu.2010.158","article-title":"AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3","volume":"24","author":"Wunderlich","year":"2010","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/bs.mcb.2022.04.002_bb0225","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1039\/C4NR01510J","article-title":"A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia","volume":"6","author":"Yang","year":"2014","journal-title":"Nanoscale"},{"issue":"12","key":"10.1016\/bs.mcb.2022.04.002_bb0230","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/adhm.201600057","article-title":"Targeted siRNA delivery using a lipo-oligoaminoamide nanocore with an influenza peptide and transferrin shell","volume":"5","author":"Zhang","year":"2016","journal-title":"Advanced Healthcare Materials"}],"container-title":["Methods in Cell Biology","Methods in Stem Cell Biology - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X22000498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X22000498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:47:25Z","timestamp":1762231645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091679X22000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323900188"],"references-count":45,"URL":"https:\/\/doi.org\/10.1016\/bs.mcb.2022.04.002","relation":{},"ISSN":["0091-679X"],"issn-type":[{"value":"0091-679X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}